prostate cancer | Research | Treatment | 12 pages | source: The New England Journal of Medicine | Added Nov 21, 2020
Intermittent versus continuous hormone therapy in patients with metastatic prostate cancer
This research evaluated whether resistance to hormone therapy can be delayed by giving therapeutic injections with hormone therapy intermittently (start and stop) instead of continuously in patients with prostate cancer.
prostate cancer | Research | Treatment | 10 pages | source: BJU international | Added Nov 19, 2020
Evaluating cabozantinib plus docetaxel and prednisone in patients with metastatic castration resistant prostate cancer
The study evaluated outcomes of combining cabozantinib (Cabometyx) with docetaxel (Taxotere) and prednisone (Deltasone) in treating patients with metastatic castration-resistant prostate cancer (mCRPC). The main finding was that the combination was safe and could possibly be effective in such patients.
prostate cancer | Research | 8 pages | source: Urologic oncology | Added Nov 13, 2020
Is lymph node density a better predictor of cancer-specific survival than number of positive lymph nodes?
This study compared the predictive ability of lymph node density and the absolute number of positive lymph nodes in patients with prostate cancer and lymph node invasion.
prostate cancer | Research | Treatment | 10 pages | source: Urologic oncology | Added Nov 11, 2020
Adding docetaxel-based chemotherapy early to hormone therapy can improve survival
This study examined the benefit of adding chemotherapy to androgen deprivation therapy (ADT) early to treat metastatic hormone-sensitive prostate cancer. Researchers reported a survival benefit when chemotherapy was added to ADT. This benefit was only detected with chemotherapy involving docetaxel (Taxotere).
prostate cancer | Research | Treatment | 10 pages | source: World Journal of Urology | Added Nov 07, 2020
Are focal therapies an option for recurrent cancer?
This review examined the safety and effectiveness of focal therapies for recurrent localized prostate cancer. The authors concluded that there is early evidence to suggest that focal therapies are well-tolerated and effective for recurrent localized prostate cancer.
prostate cancer | Treatment | 10 pages | source: International journal of urology: official journal of the Japanese Urological Association | Added Nov 05, 2020
Combining hormone therapy with additional therapies – an update
This review evaluated current evidence on combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC). Authors concluded that results are promising for the combination of taxane-based chemotherapies and alternative hormone therapies with androgen deprivation therapy (ADT).
prostate cancer | Medivizor | source: Medivizor | Added Nov 03, 2020
Colon Cancer Patient Advocate Shares Her Story
In April, the American Association for Cancer Research (AACR) held a free education event on cancer called Progress and Promise Against Cancer in Washington, D.C. Surrounded by experts in cancer research, Kim Hall Jackson shared her patient story. One evening in 2008, Jackson, an event planner, was running the mayor'sprostate cancer | Research | Treatment | 10 pages | source: Journal of clinical oncology | Added Nov 01, 2020
Increased risk of cardiovascular disease during hormone therapy
This study examined the risk of cardiovascular disease (CVD) in men undergoing treatment with androgen deprivation therapy (ADT) for prostate cancer. Researchers reported an increased CVD risk in men undergoing ADT within the first year of treatment. CVD risk was dependent on the type of ADT and the patient’s history.
prostate cancer | Research | Treatment | 10 pages | source: World Journal of Urology | Added Oct 30, 2020
Survival benefits for men treated with local therapies before starting chemotherapy
This study examined the benefits of administering local therapies before chemotherapy for prostate cancer. Researchers reported lower mortality risks for men treated with local therapies before chemotherapy.
